Masimo Appoints Tim Benner as President

Masimo, a Danaher company specializing in pulse oximetry and patient monitoring solutions, appointed Tim Benner President effective August 3, 2026. Benner joined Masimo in June 2025 and has helped shape strategy, strengthen customer relationships and guide the company through its transition following Danaher’s acquisition. He previously served as Chief Marketing and Strategy Officer and most recently as Chief Commercial Officer, leading global commercial operations, marketing, strategic growth initiatives and customer engagement. Julie Sawyer Montgomery, CEO Designate of Danaher Corporation, said Benner’s strategic leadership, customer knowledge and commitment to innovation make him suited to lead Masimo’s next chapter. Benner brings more than 30 years of medical technology experience, including senior leadership roles at Edwards Lifesciences, Abbott, Terumo, Inari Medical/Stryker and Masimo. As President, Benner will lead Masimo’s global business, with responsibility for innovation across its patient monitoring portfolio, customer partnerships, commercial growth and efforts to improve patient outcomes. He said Masimo can combine its innovation culture with the Danaher Business System to build on its technology legacy and deliver meaningful advances for clinicians and patients. Masimo develops monitoring technologies including measurements, sensors, patient monitors, automation and connectivity solutions. Its Masimo SET Measure-through Motion and Low Perfusion pulse oximetry, introduced in 1995, has outperformed other pulse oximetry technologies in more than 100 independent and objective studies. The technology is estimated to be used on more than 200 million patients worldwide annually and is the primary pulse oximetry at all 10 top U.S. hospitals in the 2026 Newsweek World’s Best Hospitals listing. Danaher’s connected life sciences and diagnostics businesses employ more than 60,000 associates worldwide. The central investor question is whether Benner can convert Masimo’s clinical reputation and Danaher’s operating system into sustained commercial growth while preserving innovation momentum.